CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
Continuous Positive Airway Pressure (CPAP)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03678311
NCT03678311N/ACompleted

Obstructive Sleep Apnea and Cardiac Electrophysiologic Biomarkers of Sudden Cardiac Death

The Cleveland Clinic·interventional·Posted Sep 19, 2018·Updated Jul 2, 2020

In Brief

A clinical study evaluating Continuous Positive Airway Pressure (CPAP) for Long QT Syndrome and Sleep Apnea. Completed, enrolled 9 participants across 1 site.

Detailed Summary

Obstructive sleep apnea (OSA) has been associated with cardiac repolarization abnormalities and implicated in sudden cardiac death. A biologically plausible mechanism by which OSA exerts this lethality is by QT interval prolongation, a known marker of ventricular tachyarrhythmias (VTA) leading to cardiac death. Congenital long QT syndrome (LQTS) is a familial arrhythmogenic disorder characterized by prolonged QT interval on the electrocardiogram and increased propensity for VTA. Preliminary data identify an association of the extent of severity of OSA and progressive prolongation of the corrected QT interval in LQTS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedSep 19, 2018
Enrollment StartMar 13, 2019
Primary CompletionApr 29, 2019
Study CompletionApr 30, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 7.8 years ago

Interventions

Continuous Positive Airway Pressure (CPAP)device

If diagnosed with Long QT Syndrome and have Sleep Apnea index \>5 pauses per hour then given CPAP to wear for approximately 3 months.